Bezlotoxumab for C. difficile Colitis — Is Timing Critical?

Efficacy of bezlotoxumab given during the treatment course for C. difficile colitis was independent of timing of administration.

C. difficile infection (CDI), the most frequent cause of healthcare-associated gastrointestinal infection in the U.S., often takes a recurrent and complicated course in patients with comorbidities. Bezlotoxumab, a recently FDA-approved monoclonal antibody directed against C. difficile toxin B, reduces recurrence in high-risk patients by ≈40% when given together with antibiotic treatment for CDI (see NEJM JW Infect Dis Jun 2017). However, the optimal time for administration of bezlotoxumab during the course of antibiotic treatment for CDI has been unclear.

A post hoc analysis of two placebo-controlled phase III studies involving 1554 patients, 781 of whom received bezlotoxumab, sheds light on timing. In these studies, 42%, 30%, and 28% of pat…

Reviewing Author

Thomas Glück, MD

Disclosures

Editorial BoardsConsilium Infectiorum by InfectoPharm, Infection

Thomas Glück, MD

Disclosures

Editorial BoardsConsilium Infectiorum by InfectoPharm, Infection

Bezlotoxumab for C. difficile Colitis — Is Timing Critical?

Topics

Reviewing Author